Menu
Search
|

Menu

Close
X

Medicines Co MDCO.OQ (NASDAQ Stock Exchange Global Select Market)

33.16 USD
+0.82 (+2.54%)
As of Feb 17
chart
Previous Close 32.34
Open 32.25
Volume 666,027
3m Avg Volume 436,630
Today’s High 33.23
Today’s Low 31.71
52 Week High 55.94
52 Week Low 24.45
Shares Outstanding (mil) 72.64
Market Capitalization (mil) 2,772.65
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.45 Mean rating from 11 analysts

KEY STATS

Revenue (mm, USD)
FY17
60
FY16
168
FY15
309
EPS (USD)
FY17
-7.386
FY16
-1.793
FY15
-3.297
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
26.22
5.77
Price to Book (MRQ)
vs sector
13.51
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
310.31
16.52
LT Debt to Equity (MRQ)
vs sector
149.03
12.22
Return on Investment (TTM)
vs sector
-62.66
14.43
Return on Equity (TTM)
vs sector
-137.15
16.13

EXECUTIVE LEADERSHIP

Fredric Eshelman
Executive Chairman of the Board, Since 2017
Salary: --
Bonus: --
Clive Meanwell
Chief Executive Officer, Director, Since 2015
Salary: $896,447.00
Bonus: --
William O'Connor
Chief Financial Officer, Since 2016
Salary: $465,000.00
Bonus: $100,000.00
Christopher Cox
Executive Vice President, Chief Corporate Development Officer, Since 2016
Salary: $422,436.00
Bonus: $100,000.00
Jeffrey Frazier
Executive Vice President, Chief Human Strategy Officer, Since 2014
Salary: $445,875.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

8 SYLVAN WAY
PARSIPPANY   NJ   07054

Phone: +1973.2906000

The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin). It also has a pipeline of products in development, including Carbavance, inclisiran and MDCO-700. Carbavance is used for the treatment of hospitalized patients with gram-negative bacterial infections. Inclisiran is used for the treatment of hypercholesterolemia. MDCO-700 includes sedative-hypnotic, which is used to induce and maintain sedation for procedural care and general anesthesia for surgical care. In addition to these products and products in development, it has a portfolio of generic drugs.

SPONSORED STORIES